Items tagged with Drug-resistant TB
In New York, video chat trumps quarantine to combat TB (post)
Thirty-four-year-old Karim works long days as an investment adviser, and when he doesn't burn the midnight oil, he plays basketball or goes to the gym, hangs out with friends, or heads to coffee shops. You wouldn't know he has an especially tough-to-treat illness.
Conflict and drug-resistant tuberculosis in Ukraine (post)
The UN released a report on Aug 29 about the worsening situation for human rights in the conflict region of Ukraine (1). An average of 36 people are killed every day and at least 260 000 people have been displaced from this region (1). Ed Holt in The Lancet (Aug 30, p 735) (2) reported about the threat to medical staff, equipment, and essential drugs, including for tuberculosis. Ukraine is one of the 27 countries in the world with a high burden of multidrug-resistant (MDR) tuberculosis and in 2012, there were an estimated 6800 new cases in the country (3).In view of the large number of people displaced, the control of tuberculosis and MDR-tuberculosis in Ukraine and surrounding countries will not only depend on the provision of medicines and health-care services in the conflict zone, but also on effective measures for detection and care of internally displaced people (IDP) and refugees.
Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound (post)
Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria
Latvia to host ground-breaking conference on TB in Europe (post)
16 December 2014 - Geneva, Switzerland - Latvia holding the Presidency of the European Union in the first half of 2015 will host the first European ministerial conference on tuberculosis and drug resistance on the 31st of March in Riga.
The Union convenes TREAT TB partners to review results of new research (post)
The Union recently brought research partners together in Washington, DC to share results from five years of TB research that began in 2009. Carried out through the TREAT TB initiative supported by the US Agency for International Development (USAID), researchers worked with the goal of improving international standards and practices for diagnosing and treating TB in order to better serve the needs of people affected by the disease.
Community of global drug-resistant tuberculosis implementers announces the "SWIFT Response Project" (post)
December 18, 2014, Cleveland, Ohio -- In response to recent reports showing both the high morbidity and mortality and high financial costs of drug-resistant tuberculosis (DR-TB), a pioneering group of international DR-TB experts has created the SWIFT Response Project. SWIFT stands for Society Working on Implementation to Fight TB and the goal of the group is to rapidly develop implementation tools to ensure optimal use of new TB drugs so as to provide the best possible outcomes for patients and programs.
New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency (post)
While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients. New research conducted at the Center for Tuberculosis Research at the Johns Hopkins University School of Medicine shows that lower doses of the toxic drug bedaquiline — given together with verapamil, a medication that’s used to treat various heart conditions — can lead to the same antibacterial effects as higher toxic doses of bedaquiline. The combination of the two drugs could potentially shorten treatment time, reduce the side effects of bedaquiline and improve patient outcomes for those suffering from TB.
Losing the fight against tuberculosis (post)
On a recent morning at Persahabatan Hospital in East Jakarta, patients, some from remote villages accessible only by boat, gathered in a waiting room. Nearby, lab technicians used new diagnostic technology to test sputum samples for multidrug-resistant tuberculosis, in an effort to tackle a growing caseload of the deadly disease.
Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios (post)
New experimental evidence on anti-TB regimes based on low-efficacious linezolid dosage to treat XDR-TB patients
India: 1st in 50 years: Nod for new tuberculosis drug (post)
With cases of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) threatening the country, Bedaquiline the first anti-TB drug manufactured after Rifampicin (almost 50 years ago) has been approved for use in India. Bedaquiline is so far approved in the US, EU and other major countries. In a recent meeting, India’s apex committee on drugs recommended waiver of local clinical trials for the drug and suggested its use under the government’s run programme for TB.
Page 11 of 117 · Total posts: 0
←First 10 11 12 Last→